Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

BACKGROUND: Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in PIK3CA gene predict worse response to neoadjuvant chemotherapy for HER2-positive patients, while their role is less clearly defined for HER2-negative tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Cocciolone, Valentina, Cannita, Katia, Tessitore, Alessandra, Mastroiaco, Valentina, Rinaldi, Lucia, Paradisi, Stefania, Irelli, Azzurra, Baldi, Paola Lanfiuti, Sidoni, Tina, Ricevuto, Enrico, Dal Mas, Antonella, Calvisi, Giuseppe, Coletti, Gino, Ciccozzi, Antonietta, Pizzorno, Laura, Resta, Valter, Bafile, Alberto, Alesse, Edoardo, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007957/
https://www.ncbi.nlm.nih.gov/pubmed/29937992
http://dx.doi.org/10.18632/oncotarget.25270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007957/
https://www.ncbi.nlm.nih.gov/pubmed/29937992
http://dx.doi.org/10.18632/oncotarget.25270

Ejemplares similares